Genetic variations in the regulator of G-protein signaling genes are associated with survival in late-stage non-small cell lung cancer

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Dai, Jingyao ^a   Gu, Jian ^a   Lu, Charles ^a   Lin, Jie ^a   Stewart, David ^a   Chang, David ^a   Roth, Jack A ^a   Wu, Xifeng ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RGS PROTEIN; ANTINEOPLASTIC AGENT; GUANINE NUCLEOTIDE BINDING PROTEIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; FEMALE; GENE; GENE INTERACTION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HIGH RISK PATIENT; HOMOZYGOSITY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIGENE FAMILY; OVERALL SURVIVAL; RGS GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME; AGED; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIOTHERAPY; SIGNAL TRANSDUCTION; SURVIVAL;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FEMALE; GENETIC VARIATION; GENOTYPE; GTP-BINDING PROTEINS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RADIOTHERAPY; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS;

EID: 79959226617     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021120     Document Type: Article

References (56)

1. Parkin DM, (2001) Global cancer statistics in the year 2000. Lancet Oncol 2: 533-543.
2. Stinchcombe TE, Fried D, Morris DE, Socinski MA, (2006) Combined modality therapy for stage III non-small cell lung cancer. Oncologist 11: 809-823.
3. Fournel P, Robinet G, Thomas P, Souquet PJ, Lena H, et al. (2005) Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 23: 5910-5917.
4. Penland SK, Socinski MA, (2004) Management of unresectable stage III non-small cell lung cancer: the role of combined chemoradiation. Semin Radiat Oncol 14: 326-334.
5. van Meerbeeck JP, Koning CC, Tjan-Heijnen VC, Boekema AG, Kaandorp CJ, et al. (2005) [Guideline on 'non-small cell lung carcinoma; staging and treatment']. Ned Tijdschr Geneeskd 149: 72-77.
6. Exton JH, (1997) Cell signalling through guanine-nucleotide-binding regulatory proteins (G proteins) and phospholipases. Eur J Biochem 243: 10-20.
7. Oldham WM, Hamm HE, (2008) Heterotrimeric G protein activation by G-protein-coupled receptors. Nat Rev Mol Cell Biol 9: 60-71.
8. Hurst JH, Hooks SB, (2009) Regulator of G-protein signaling (RGS) proteins in cancer biology. Biochem Pharmacol 78: 1289-1297.
9. Manzur M, Hamzah J, Ganss R, (2009) Modulation of g protein signaling normalizes tumor vessels. Cancer Res 69: 396-399.
10. Berman DM, Gilman AG, (1998) Mammalian RGS proteins: barbarians at the gate. J Biol Chem 273: 1269-1272.
11. De Vries L, Zheng B, Fischer T, Elenko E, Farquhar MG, (2000) The regulator of G protein signaling family. Annu Rev Pharmacol Toxicol 40: 235-271.
12. Hollinger S, Hepler JR, (2002) Cellular regulation of RGS proteins: modulators and integrators of G protein signaling. Pharmacol Rev 54: 527-559.
13. Burchett SA, (2000) Regulators of G protein signaling: a bestiary of modular protein binding domains. J Neurochem 75: 1335-1351.
14. Gu S, Cifelli C, Wang S, Heximer SP, (2009) RGS proteins: identifying new GAPs in the understanding of blood pressure regulation and cardiovascular function. Clin Sci (Lond) 116: 391-399.
15. Hendriks-Balk MC, Peters SL, Michel MC, Alewijnse AE, (2008) Regulation of G protein-coupled receptor signalling: focus on the cardiovascular system and regulator of G protein signalling proteins. Eur J Pharmacol 585: 278-291.
16. Riddle EL, Schwartzman RA, Bond M, Insel PA, (2005) Multi-tasking RGS proteins in the heart: the next therapeutic target? Circ Res 96: 401-411.
17. Traynor J Regulator of G protein-signaling proteins and addictive drugs. Ann N Y Acad Sci 1187: 341-352.
18. Hurst JH, Mendpara N, Hooks SB, (2009) Regulator of G-protein signalling expression and function in ovarian cancer cell lines. Cell Mol Biol Lett 14: 153-174.
19. Grunebach F, Erndt S, Hantschel M, Heine A, Brossart P, (2008) Generation of antigen-specific CTL responses using RGS1 mRNA transfected dendritic cells. Cancer Immunol Immunother 57: 1483-1491.
20. Rangel J, Nosrati M, Leong SP, Haqq C, Miller JR, 3rd, et al. (2008) Novel role for RGS1 in melanoma progression. Am J Surg Pathol 32: 1207-1212.
21. Furuya M, Nishiyama M, Kimura S, Suyama T, Naya Y, et al. (2004) Expression of regulator of G protein signalling protein 5 (RGS5) in the tumour vasculature of human renal cell carcinoma. J Pathol 203: 551-558.
22. Rae FK, Stephenson SA, Nicol DL, Clements JA, (2000) Novel association of a diverse range of genes with renal cell carcinoma as identified by differential display. Int J Cancer 88: 726-732.
23. Han JI, Huang NN, Kim DU, Kehrl JH, (2006) RGS1 and RGS13 mRNA silencing in a human B lymphoma line enhances responsiveness to chemoattractants and impairs desensitization. J Leukoc Biol 79: 1357-1368.
24. Islam TC, Asplund AC, Lindvall JM, Nygren L, Liden J, et al. (2003) High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of Cyclin D1 in mantle cell lymphoma. Leukemia 17: 1880-1890.
25. Tsai CC, Huang KW, Chen HF, Zhan BW, Lai YH, et al. (2006) Gene expression analysis of human hepatocellular carcinoma by using full-length cDNA library. J Biomed Sci 13: 241-249.
26. Chen X, Higgins J, Cheung ST, Li R, Mason V, et al. (2004) Novel endothelial cell markers in hepatocellular carcinoma. Mod Pathol 17: 1198-1210.
27. Silva AP, Salim AC, Bulgarelli A, de Souza JE, Osorio E, et al. (2003) Identification of 9 novel transcripts and two RGSL genes within the hereditary prostate cancer region (HPC1) at 1q25. Gene 310: 49-57.
28. Sood R, Bonner TI, Makalowska I, Stephan DA, Robbins CM, et al. (2001) Cloning and characterization of 13 novel transcripts and the human RGS8 gene from the 1q25 region encompassing the hereditary prostate cancer (HPC1) locus. Genomics 73: 211-222.
29. Wiechec E, Overgaard J, Hansen LL, (2008) A fragile site within the HPC1 region at 1q25.3 affecting RGS16, RGSL1, and RGSL2 in human breast carcinomas. Genes Chromosomes Cancer 47: 766-780.
30. Smalley MJ, Iravani M, Leao M, Grigoriadis A, Kendrick H, et al. (2007) Regulator of G-protein signalling 2 mRNA is differentially expressed in mammary epithelial subpopulations and over-expressed in the majority of breast cancers. Breast Cancer Res 9: R85.
31. Nikolova DN, Zembutsu H, Sechanov T, Vidinov K, Kee LS, et al. (2008) Genome-wide gene expression profiles of thyroid carcinoma: Identification of molecular targets for treatment of thyroid carcinoma. Oncol Rep 20: 105-121.
32. Tonjes A, Miedlich S, Holzapfel HP, Eszlinger M, Arkenau C, et al. (2004) Expression of regulators of g protein signaling mRNA is differentially regulated in hot and cold thyroid nodules. Thyroid 14: 896-901.
33. Hamzah J, Jugold M, Kiessling F, Rigby P, Manzur M, et al. (2008) Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 453: 410-414.
34. Schwable J, Choudhary C, Thiede C, Tickenbrock L, Sargin B, et al. (2005) RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation. Blood 105: 2107-2114.
35. Koga H, Imada K, Ueda M, Hishizawa M, Uchiyama T, (2004) Identification of differentially expressed molecules in adult T-cell leukemia cells proliferating in vivo. Cancer Sci 95: 411-417.
36. Tatenhorst L, Senner V, Puttmann S, Paulus W, (2004) Regulators of G-protein signaling 3 and 4 (RGS3, RGS4) are associated with glioma cell motility. J Neuropathol Exp Neurol 63: 210-222.
37. Gu J, Wu X, Dong Q, Romeo MJ, Lin X, et al. (2006) A nonsynonymous single-nucleotide polymorphism in the PDZ-Rho guanine nucleotide exchange factor (Ser1416Gly) modulates the risk of lung cancer in Mexican Americans. Cancer 106: 2716-2724.
38. Wang J, Lippman SM, Lee JJ, Yang H, Khuri FR, et al. (2010) Genetic variations in regulator of G-protein signaling genes as susceptibility loci for second primary tumor/recurrence in head and neck squamous cell carcinoma. Carcinogenesis 31: 1755-1761.
39. You M, Wang D, Liu P, Vikis H, James M, et al. (2009) Fine mapping of chromosome 6q23-25 region in familial lung cancer families reveals RGS17 as a likely candidate gene. Clin Cancer Res 15: 2666-2674.
40. Berman DM, Wang Y, Liu Z, Dong Q, Burke LA, et al. (2004) A functional polymorphism in RGS6 modulates the risk of bladder cancer. Cancer Res 64: 6820-6826.
41. Hildebrandt MA, Gu J, Wu X, (2009) Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert Opin Drug Metab Toxicol 5: 745-755.
42. Sliva D, (2004) Signaling pathways responsible for cancer cell invasion as targets for cancer therapy. Curr Cancer Drug Targets 4: 327-336.
43. Sarkar FH, Li Y, (2004) Cell signaling pathways altered by natural chemopreventive agents. Mutat Res 555: 53-64.
44. Puiffe ML, Le Page C, Filali-Mouhim A, Zietarska M, Ouellet V, et al. (2007) Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer. Neoplasia 9: 820-829.
45. Albig AR, Schiemann WP, (2005) Identification and characterization of regulator of G protein signaling 4 (RGS4) as a novel inhibitor of tubulogenesis: RGS4 inhibits mitogen-activated protein kinases and vascular endothelial growth factor signaling. Mol Biol Cell 16: 609-625.
46. Xiao B, Zhang Y, Niu WQ, Gao PJ, Zhu DL, (2009) Haplotype-based association of regulator of G-protein signaling 5 gene polymorphisms with essential hypertension and metabolic parameters in Chinese. Clin Chem Lab Med 47: 1483-1488.
47. Boss CN, Grunebach F, Brauer K, Hantschel M, Mirakaj V, et al. (2007) Identification and characterization of T-cell epitopes deduced from RGS5, a novel broadly expressed tumor antigen. Clin Cancer Res 13: 3347-3355.
48. Siderovski DP, Willard FS, (2005) The GAPs, GEFs, and GDIs of heterotrimeric G-protein alpha subunits. Int J Biol Sci 1: 51-66.
49. Ishii M, Kurachi Y, (2003) Physiological actions of regulators of G-protein signaling (RGS) proteins. Life Sci 74: 163-171.
50. Ooe A, Kato K, Noguchi S, (2007) Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers. Breast Cancer Res Treat 101: 305-315.
51. Takahashi H, Nemoto T, Yoshida T, Honda H, Hasegawa T, (2006) Cancer diagnosis marker extraction for soft tissue sarcomas based on gene expression profiling data by using projective adaptive resonance theory (PART) filtering method. BMC Bioinformatics 7: 399.
52. Martinez-Cardus A, Martinez-Balibrea E, Bandres E, Malumbres R, Gines A, et al. (2009) Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancer. Mol Cancer Ther 8: 194-202.
53. Benzing T, Brandes R, Sellin L, Schermer B, Lecker S, et al. (1999) Upregulation of RGS7 may contribute to tumor necrosis factor-induced changes in central nervous function. Nat Med 5: 913-918.
54. Balkwill F, (2009) Tumour necrosis factor and cancer. Nat Rev Cancer 9: 361-371.
55. Wu X, Spitz MR, Lee JJ, Lippman SM, Ye Y, et al. (2009) Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev Res (Phila) 2: 617-624.
56. Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, et al. (2008) Cumulative association of five genetic variants with prostate cancer. N Engl J Med 358: 910-919.